Payment overview · 2025
General Payments
$474.18
29 reported records · 9 companies
Healthcare provider profile · identity verified
Ryan Batson Smithee, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · AMARILLO, TX · NPI 1861924623
Verified facts
What the public records show
CMS Open Payments records show Ryan Batson Smithee, M.D. received $474.18 in general payments during 2025 across 29 reported records.
Lilly USA, LLC accounted for 33.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $156.38 | 33.0% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $85.65 | 18.1% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $66.88 | 14.1% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $56.84 | 12.0% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $40.82 | 8.6% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $21.13 | 4.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.24 | 3.9% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $14.24 | 3.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.00 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $474.18 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $142.86 | 9 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $142.86 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $65.30 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $65.30 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $49.13 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $49.13 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $40.82 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $40.82 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $34.17 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $22.67 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $21.13 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.35 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.24 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.75 | 1 | 2025 |
Source payment records
|
|||||
| BOOSTRIX Normalized: boostrix |
Biological | GlaxoSmithKline, LLC. | $16.42 | 1 | 2025 |
Source payment records
|
|||||
| FLULAVAL QUADRIVALENT Normalized: flulaval quadrivalent |
Biological | GlaxoSmithKline, LLC. | $14.34 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $14.24 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.00 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $13.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 87 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 108 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 89 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 94 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
87 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
108 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
89 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
94 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
98 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 685 | 165 |
| Atorvastatin Calcium | Atorvastatin Calcium | 331 | 87 |
| Amlodipine Besylate | Amlodipine Besylate | 312 | 77 |
| Losartan Potassium | Losartan Potassium | 304 | 78 |
| Gabapentin | Gabapentin | 254 | 57 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 247 | 65 |
| Metformin Hcl | Metformin Hcl | 244 | 69 |
| Potassium Chloride | Potassium Chloride | 191 | 56 |
| Omeprazole | Omeprazole | 184 | 51 |
| Lisinopril | Lisinopril | 181 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 157 | 38 |
| Sertraline Hcl | Sertraline Hcl | 147 | 35 |
| Simvastatin | Simvastatin | 143 | 33 |
| Allopurinol | Allopurinol | 138 | 34 |
| Alendronate Sodium | Alendronate Sodium | 127 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 122 | 31 |
| Amitriptyline Hcl | Amitriptyline Hcl | 119 | 26 |
| Jardiance | Empagliflozin | 108 | 19 |
| Eliquis | Apixaban | 98 | 19 |
| Montelukast Sodium | Montelukast Sodium | 97 | 24 |
| Ozempic | Semaglutide | 94 | 20 |
| Ezetimibe | Ezetimibe | 90 | 21 |
| Mounjaro | Tirzepatide | 89 | 15 |
| Farxiga | Dapagliflozin Propanediol | 87 | 18 |
| Carvedilol | Carvedilol | 85 | 26 |
| Furosemide | Furosemide | 84 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 79 | 17 |
| Meloxicam | Meloxicam | 76 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 70 | 21 |
| Metformin Hcl Er | Metformin Hcl | 70 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 69 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 68 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 61 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 57 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 17 |
| Atenolol | Atenolol | 49 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 49 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 48 | 14 |
| Glimepiride | Glimepiride | 47 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 46 | suppressed |
| Nifedipine Er | Nifedipine | 46 | 12 |
| Synthroid | Levothyroxine Sodium | 44 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 41 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 41 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 41 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 40 | suppressed |
| Temazepam | Temazepam | 38 | suppressed |
| Celecoxib | Celecoxib | 36 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 33 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 32 | 12 |
| Estradiol | Estradiol | 30 | 11 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 28 | suppressed |
| Gemfibrozil | Gemfibrozil | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 24 | suppressed |
| Alprazolam | Alprazolam | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 22 | suppressed |
| Lorazepam | Lorazepam | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Nadolol | Nadolol | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 18 |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Eplerenone | Eplerenone | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Glyburide | Glyburide | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 15 |
| Breyna | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Prolia | Denosumab | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Famotidine | Famotidine | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Azithromycin | Azithromycin | 12 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Zafirlukast | Zafirlukast | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Klor-Con 10 | Potassium Chloride | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Np Thyroid | Thyroid,pork | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $474.18 · 29 records | Lilly USA, LLC | AIRSUPRA, AREXVY, BOOSTRIX, EVENITY, FARXIGA, FLULAVAL QUADRIVALENT, JARDIANCE, Korlym, MOUNJARO, NURTEC ODT, Ozempic, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, VOQUEZNA, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error